Bispecific Antibodies in Relapsed/Refractory DLBCL
Follow-up data from the EPCORE NHL-1 trial lend further support to the efficacy and safety of…
Browsing Tag
Bispecific
Global Bispecific Antibodies Cumulative Sales USD 90 Billion By 2028
Delhi, June 26, 2023 (GLOBE NEWSWIRE) -- Global Bispecific Antibody Market Opportunity & Clinical Trials Insight 2023 Report Highlights: Yearly & Quarterly Sales Insight (2018…
New Bispecific Antibody Approved for Tough-to-Treat Lymphoma
The FDA has granted accelerated approval to glofitamab (Columvi) for adults…
Phase II Study: Bispecific Oral Drug Tops Leading JAK Inhibitor for RA
MILAN -- A novel oral agent that blocks two different kinase enzymes was possibly more effective against…
LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager…
Through a research collaboration with Janssen, a lead candidate was identified for further development towards clinical studies.In May 2020, LAVA entered into a research collaboration and…
Bispecific Antibody Approved for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
The FDA granted accelerated approval to epcoritamab (Epkinly) for the treatment of adults with relapsed or…
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific…
<!-- Name:DistributionId Value:8839036 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Novel Bispecific Antibody Active in Recurrent/Metastatic Head and Neck Cancer
ORLANDO -- More than a third of patients with previously treated head and neck cancer responded to a novel bispecific antibody,…
Bispecific Antibody Active in Relapsed/Refractory Small Cell Lung Cancer
A first-in-class bispecific antibody achieved durable responses in a fourth of patients with…
CytomX Therapeutics Announces Milestone Achievement in Probody® T-Cell Engaging…
-Achievement of clinical candidate is the first in the multi-target collaboration and triggers a $5 million milestone payment to CytomX- -CytomX-retained US co-commercialization and…